Prinomastat hydrochloride is primarily used in the field of cancer research and treatment. It functions as a matrix metalloproteinase (MMP) inhibitor, targeting enzymes that play a role in tumor growth and metastasis. By inhibiting these enzymes, it helps in slowing down the progression of certain types of cancers. This compound has been studied in clinical trials for its potential to enhance the effectiveness of chemotherapy and radiation therapy. Additionally, it is explored for its application in treating conditions where MMP activity is detrimental, such as in certain inflammatory diseases and disorders involving tissue degradation. Its role in these areas makes it a valuable compound in the development of therapeutic strategies aimed at controlling cancer and other MMP-related pathologies.